全文获取类型
收费全文 | 2068篇 |
免费 | 101篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 21篇 |
妇产科学 | 8篇 |
基础医学 | 220篇 |
口腔科学 | 3篇 |
临床医学 | 201篇 |
内科学 | 295篇 |
皮肤病学 | 17篇 |
神经病学 | 86篇 |
特种医学 | 75篇 |
外科学 | 552篇 |
综合类 | 124篇 |
现状与发展 | 2篇 |
预防医学 | 12篇 |
眼科学 | 2篇 |
药学 | 370篇 |
1篇 | |
中国医学 | 16篇 |
肿瘤学 | 169篇 |
出版年
2023年 | 45篇 |
2022年 | 59篇 |
2021年 | 77篇 |
2020年 | 71篇 |
2019年 | 71篇 |
2018年 | 57篇 |
2017年 | 56篇 |
2016年 | 43篇 |
2015年 | 39篇 |
2014年 | 69篇 |
2013年 | 100篇 |
2012年 | 59篇 |
2011年 | 60篇 |
2010年 | 61篇 |
2009年 | 62篇 |
2008年 | 75篇 |
2007年 | 66篇 |
2006年 | 70篇 |
2005年 | 54篇 |
2004年 | 56篇 |
2003年 | 56篇 |
2002年 | 39篇 |
2001年 | 34篇 |
2000年 | 30篇 |
1999年 | 40篇 |
1998年 | 36篇 |
1997年 | 31篇 |
1996年 | 41篇 |
1995年 | 41篇 |
1994年 | 31篇 |
1993年 | 34篇 |
1992年 | 26篇 |
1991年 | 34篇 |
1990年 | 32篇 |
1989年 | 31篇 |
1988年 | 35篇 |
1987年 | 32篇 |
1986年 | 23篇 |
1985年 | 35篇 |
1984年 | 34篇 |
1983年 | 22篇 |
1982年 | 35篇 |
1981年 | 30篇 |
1980年 | 28篇 |
1979年 | 21篇 |
1978年 | 20篇 |
1977年 | 21篇 |
1976年 | 19篇 |
1975年 | 10篇 |
1973年 | 11篇 |
排序方式: 共有2184条查询结果,搜索用时 31 毫秒
1.
2.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
3.
卵巢癌的临床早期症状不明显,筛查手段有限,就诊时常处于晚期阶段,5年生存率仅30%~45%,严重威胁着女性健康。免疫治疗尤其是免疫检查点抑制剂治疗因其持久的抗肿瘤效应已被批准用于晚期或复发性的多种类型癌症的治疗。目前免疫治疗的一些研究进展为卵巢癌患者的临床管理提供了新的机遇与挑战。 相似文献
4.
BackgroundImmunotherapy has made encouraging progress in the treatment of urothelial carcinoma, but only a small percentage of patients respond effectively to the immune checkpoint blockade (ICB). Our study aims to develop a classifier could effectively predict the response to ICB.MethodsSupport vector machines recursive feature elimination (SVM-RFE) algorithm was used to feature selection, then compared nine common binary classification algorithms through machine learning, we selected the classifier with the highest prediction performance (LASSO logistics classifier). Ten-fold cross-validation was used to avoid the overfitting effect.ResultsWe developed a classifier on a urothelial carcinoma cohort treated with PD-L1 inhibitor Atzolizumab (IMvigor210 cohort, n = 272) and calculated a tumor mutational burden-related LASSO score (TLS) using the LASSO algorithm, which was significantly correlated with Tumor mutational burden (TMB) and neoantigen burden. We validated the efficacy of TLS in predicting prognosis and immunotherapy benefit in internal (IMvigor210) and external validation set (TCGA-BLCA, n = 406), respectively.ConclusionsAfter in-depth analysis, we provide a new idea for stratified treatment of such patients, that is, patients with high TLS should use ICB and also may benefit from hormone therapy, while patients with low TLS respond poorly to ICB and maybe benefit from targeting TGFβ. 相似文献
5.
Despite a decline in the incidence of squamous cell carcinomas (SCCs) over the past 20 years, their survival rate has remained nearly the same, indicating that treatment options have not improved relative to other cancer types. Immunotherapies have a high potential for a sustained effect in SCC patients, but their response rate is low. Here, we review the suppressive role of transforming growth factor-beta (TGFβ) on the antitumor immune response in SCC and present its potential as a therapeutic target in combination with the current range of immunotherapies available for SCC patients. We conclude that SCCs are an optimal cancer type to study the effectiveness of TGFβ inhibition due to the prevalence of dysregulated TGFβ signaling in them. 相似文献
6.
Jun Zhu Liang Wang Yifan Zhou Jun Hao Shuai Wang Lei Liu Jipeng Li 《Journal of gastrointestinal oncology.》2020,11(6):1381
BackgroundThe innovation of immune checkpoint blockade (ICB) represents a promising shift in the treatment of advanced hepatocellular carcinoma (HCC). However, response to ICB has varied largely due to the high tumor heterogeneity and complex tumor microenvironment (TME). The competitive endogenous RNA (ceRNA) network also plays an important role in tumor occurrence and progression, but its relation with tumor-infiltrating immune cells (TICs) remains largely unexplored in HCC. The overriding objective of our study was thus to construct a prognosis-related risk model and to further evaluate the relationship between ceRNA networks and TICs.MethodsDifferentially expressed gene (DEG) analysis was performed to identify the differentially expressed RNAs. Lasso and multivariable Cox regression analyses were used to construct risk models, which were assessed by the area under the receiver operating characteristic curve (AUC of ROC) and Kaplan-Meier (K-M) curves. Then, a single-sample gene set enrichment analysis (ssGSEA) algorithm was adopted to dissect the TICs in HCC samples. Nomograms were constructed and calibration curves were used to verify the discrimination and accuracy of the nomograms. Finally, integration analysis was performed to validate the correlation of ceRNA and TICs.ResultsIn the study, 7 differentially expressed RNAs [5 messenger RNA s (mRNAs) and 2 micro RNAs (miRNAs)] were incorporated to construct a ceRNA risk model. The AUC of the 1-, 3-, and 5-year overall survival (OS) were 0.784, 0.685, and 0.691 respectively. Likewise, 7 types TICs were in the TICs signature model and the AUC of the 1-, 3-, and 5-year OS were 0.706, 0.731, and 0.721 respectively. The integration analysis showed that 7 pairs of mRNA-TICs and 1 pair of miRNA-TICs had a close relation (all correlation coefficients >0.2, P<0.001).ConclusionsThrough constructing two risk models based on ceRNA network and TICs, we identified the hub RNAs and key TICs in the progression and prognosis of HCC, and further explored the relationship between ceRNA and TME. Importantly, targeting these hub RNAs may facilitate the remodeling of the TME and be a potential therapeutic alternative to enhancing the response to ICB, thus improving the prognosis of HCC patients. 相似文献
7.
8.
9.
10.
《Clinical breast cancer》2020,20(3):238-245
BackgroundThe purpose of this study was to investigate whether combining pembrolizumab with palliative radiation therapy (RT) improves outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).Patients and MethodsEligible patients had HR+/human epidermal growth factor receptor 2-negative MBC; were candidates for RT to ≥ 1 bone, soft tissue, or lymph node lesion; and had ≥ 1 lesion outside the RT field. Patients received 200 mg pembrolizumab intravenously 2 to 7 days prior to RT and on day 1 of repeating 21-day cycles. RT was delivered to a previously unirradiated area in 5 treatments each of 4 Gy. The primary endpoint was objective response rate. The study used a 2-stage design: 8 women were enrolled into the first stage, and if at least 1 of 8 patients experienced an objective response, 19 more would be enrolled. Secondary endpoints included progression-free survival, overall survival, and safety. Exploratory endpoints included association of overall response rate with programmed death-ligand 1 status and tumor-infiltrating lymphocytes.ResultsEight patients were enrolled in stage 1. The median age was 59 years, and the median prior lines of chemotherapy for metastatic disease was 2. There were no objective responses, and the study was closed to further accrual. The median progression-free survival was 1.4 months (95% confidence interval, 0.4-2.1 months), and the median overall survival was 2.9 months (95% confidence interval, 0.9-3.6 months). All-cause adverse events occurred in 87.5% of patients, including just 1 grade 3 event (elevation of aspartate aminotransferase).ConclusionsRT combined with pembrolizumab did not produce an objective response in patients with heavily pre-treated HR+ MBC. Future studies should consider alternative radiation dosing and fractionation in patients with less heavily pre-treated HR+ MBC. 相似文献